Published in J Immunol on February 08, 2010
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J Invest Dermatol (2013) 1.58
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 1.55
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood (2013) 1.44
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 1.43
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol (2011) 1.37
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol (2012) 1.30
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med (2012) 1.14
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol (2010) 1.05
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol (2014) 1.04
Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat (2013) 1.04
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res (2013) 1.02
Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res (2012) 1.01
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) (2011) 0.99
HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget (2014) 0.97
Multiplex IP-FCM (immunoprecipitation-flow cytometry): Principles and guidelines for assessing physiologic protein-protein interactions in multiprotein complexes. Methods (2011) 0.96
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 0.95
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother (2013) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Distinct responses of splenic dendritic cell subsets to infection with Listeria monocytogenes: maturation phenotype, level of infection, and T cell priming capacity ex vivo. Cell Immunol (2011) 0.94
The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med (2016) 0.93
Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. J Transl Med (2013) 0.93
Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology (2013) 0.93
Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol (2012) 0.92
Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J Immunol (2014) 0.90
Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol (2012) 0.90
Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res (2015) 0.90
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm (2016) 0.89
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget (2015) 0.87
Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World J Surg Oncol (2015) 0.87
The liver works as a school to educate regulatory immune cells. Cell Mol Immunol (2013) 0.86
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol (2013) 0.86
Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol (2010) 0.85
Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol (2011) 0.85
Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol (2010) 0.84
Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One (2012) 0.84
Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS One (2013) 0.83
Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors. PLoS One (2013) 0.82
Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol (2015) 0.82
Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res (2015) 0.82
Myeloid-derived cells are key targets of tumor immunotherapy. Oncoimmunology (2014) 0.82
The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget (2016) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget (2016) 0.81
Immunological deregulation in classic hodgkin lymphoma. Mediterr J Hematol Infect Dis (2014) 0.81
Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1. J Immunol (2016) 0.80
Hiding the road signs that lead to tumor immunity. J Exp Med (2011) 0.80
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget (2016) 0.79
Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann Hematol (2013) 0.79
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin Dev Immunol (2010) 0.79
Myeloid-Derived Suppressor Cells in Bacterial Infections. Front Cell Infect Microbiol (2016) 0.78
Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. PLoS One (2015) 0.78
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget (2016) 0.78
Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment. Cancer Treat Rev (2013) 0.78
Analysis of monocytic and granulocytic myeloid-derived suppressor cells subsets in patients with hepatitis C virus infection and their clinical significance. Biomed Res Int (2015) 0.77
Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. Sci Rep (2016) 0.77
Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity. Oncoimmunology (2012) 0.77
Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther (2014) 0.77
Melanoma exosomes enable tumor tolerance in lymph nodes. Med Hypotheses (2016) 0.77
Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J (2010) 0.77
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells. J Immunother Cancer (2014) 0.76
Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes. Med Hypotheses (2016) 0.76
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. PLoS One (2016) 0.75
Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype. PLoS Pathog (2017) 0.75
The spleen as an extramedullary source of inflammatory cells responding to acetaminophen-induced liver injury. Toxicol Appl Pharmacol (2016) 0.75
Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. Vet Comp Oncol (2012) 0.75
IL-6 Improves the Nitric Oxide-Induced Cytotoxic CD8+ T Cell Dysfunction in Human Chagas Disease. Front Immunol (2016) 0.75
One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer Metastasis Rev (2016) 0.75
Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone. Front Immunol (2016) 0.75
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol (2016) 0.75
Induction of Suppressor Cells and Increased Tumor Growth following Chronic Psychosocial Stress in Male Mice. PLoS One (2016) 0.75
Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control. Oncotarget (2017) 0.75
Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines (Basel) (2016) 0.75
The Phenotype and Function of Myeloid-derived Suppressor Cells Induced by Porphyromonas gingivalis Infection. Infect Immun (2017) 0.75
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 3.81
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
Protein tyrosine phosphatases and the immune response. Nat Rev Immunol (2005) 2.88
TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol (2004) 2.11
TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol (2006) 2.05
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity (2008) 1.85
Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A (1996) 1.79
Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity (2006) 1.72
T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J Exp Med (2005) 1.69
Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer Res (2007) 1.58
High-sensitivity detection and quantitative analysis of native protein-protein interactions and multiprotein complexes by flow cytometry. Sci STKE (2007) 1.51
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Signaling defects in anti-tumor T cells. Immunol Rev (2008) 1.28
Initiation of TCR signaling: regulation within CD3 dimers. Immunol Rev (2003) 1.20
Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med (1995) 1.20
Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol (2005) 1.18
Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother (2007) 1.13
DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther (2001) 1.11
Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol (2003) 1.08
Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol (1997) 1.05
Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother (2008) 1.02
The adaptive immune response to sporadic cancer. Immunol Rev (2007) 1.02
Transcriptional basis of lymphocyte tolerance. Immunol Rev (2006) 1.01
Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res (1995) 0.95
Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur J Immunol (2004) 0.95
T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity. J Exp Med (1995) 0.93
Do structural changes of T cell receptor complex occur in tumor-bearing state? Jpn J Cancer Res (1995) 0.92
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 2.94
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother (2002) 2.60
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood (2003) 2.41
Myeloid-derived suppressor cells in human cancer. Cancer J (2010) 2.36
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Different T cell receptor signals determine CD8+ memory versus effector development. Science (2009) 2.08
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol (2011) 2.06
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 2.06
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res (2003) 2.00
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 1.99
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol (2013) 1.81
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J Exp Med (2005) 1.69
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood (2007) 1.65
Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol (2005) 1.61
Myeloid-derived suppressor cells. Adv Exp Med Biol (2007) 1.55
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res (2009) 1.49
Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. Immunity (2009) 1.37
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr Cancer Drug Targets (2007) 1.37
Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol (2013) 1.34
Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev (2006) 1.32
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest (2006) 1.26
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood (2006) 1.25
T cell division and death are segregated by mutation of TCRbeta chain constant domains. Immunity (2004) 1.24
Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol (2002) 1.21
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res (2003) 1.16
Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 1.15
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res (2002) 1.15
In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res (2008) 1.14
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother (2007) 1.13
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther (2010) 1.12
PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol (2010) 1.11
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology (2014) 1.10
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res (2012) 1.10
Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine (2005) 1.08
Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res (2007) 1.08
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
Regulatory myeloid suppressor cells in health and disease. Cancer Res (2009) 1.07
Retracted B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A (2005) 1.07
Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother (2013) 1.07
Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07
Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05
Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother (2008) 1.04
Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol (2008) 1.03
IP-FCM: immunoprecipitation detected by flow cytometry. J Vis Exp (2010) 1.03
Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother (2008) 1.02
Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res (2002) 1.02
Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res (2013) 1.02
BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother (2012) 1.02
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother (2012) 1.01
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01
Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res (2012) 1.01
Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res (2002) 1.00
Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets (2007) 1.00
T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol (2006) 1.00
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer (2007) 1.00